M. Sextro

发表

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of Hematology.

Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

V. Diehl, N. Schmitz, J. Franklin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma.

V. Diehl, J. Franklin, T. Marafioti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

V. Diehl, N. Harris, E. Jaffe, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

V. Diehl, R. Fisher, D. Crowther, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

V. Diehl, N. Harris, E. Jaffe, 2000, Blood.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Dirk Hasenclever, Markus Sieber, Norbert Schmitz, 2002, The Lancet.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, M. Pfreundschuh, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels

V. Diehl, H. Tesch, H. Bohlen, 2000, Annals of Hematology.

Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks.

D. Hasenclever, M. Sextro, Dirk Hasenclever, 1996, Bone marrow transplantation.